Together, our findings implicate that besides eNOS-NO as potential targets, targeting its upstream regulators (ERRα and ERG) could also be the PCSC-directed therapeutic strategy for the management of advanced prostate cancer, particularly the aggressive cancer carrying with the TMPRSS2:ERG fusion gene. The gene discussed is ERG; the disease is prostate cancer.